Predictive oncology adjourns special meeting of stockholders

Minneapolis, aug. 11, 2021 (globe newswire) -- predictive oncology (nasdaq: poai), a knowledge-driven company focused on applying artificial intelligence (“ai”) to personalized medicine and drug discovery, announced today that the company's special meeting of stockholders, which was convened at 3:00 p.m. central time on august 10, 2021, has been adjourned for the purpose of soliciting more votes on the proposal to approve an amendment to the company's certificate of incorporation to increase the number of authorized shares of company common stock from 100,000,000 to 200,000,000 (the “charter proposal”). the special meeting has been scheduled to reconvene on august 17, 2021 at 3:00 p.m. central time at the offices of maslon llp, 3300 wells fargo center, 90 south seventh street, minneapolis, mn 55402.
POAI Ratings Summary
POAI Quant Ranking